Ultra-Sensitive LC-MS/MS Method for the Trace Level Quantification of Six Potential Genotoxic Nitrosamine Impurities in Telmisartan
- 1 Center for Chemical Sciences and Technology, Institute of Science and Technology, Jawaharlal Nehru Technological University Hyderabad, Hyderabad, India
- 2 Aurobindo Pharma Laboratory Research Center II, Hyderabad, India
- 3 Center for Chemical Sciences and Technology, Institute of Science and Technology, Jawaharlal Nehru Technological University Hyderabad, Hyderabad, India
Abstract
Nitrosamine impurities are potentially genotoxic which are considered under cohort of concern as per ICH M7 guidelines and need to be controlled at trace levels during quantification in drug substances and drug products for safe human consumption. Recent regulatory requirements also suggest the need to have highly sensitive analytical methods for the accurate quantification of Nitrosamine impurities. In this paper we have presented simple, rapid and ultra-sensitive LC-MS/MS method for six potential genotoxic nitrosamine impurities: N-Nitroso dimethyl amine (NDMA), N-Nitroso diethyl amine (NDEA), N-Nitroso Ethyl Iso propylamine (NEIPA), N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) N-Nitroso diisopropylamino (NDIPA) and N-Nitroso dibutyl amine (NDBA) with a LOQ of 0.004 ppm. Chromatographic separation is achieved using Zorbax SB C18 150 × 3.0 mm, 3.5 μ column with 0.1% formic acid in water as mobile phase A and 0.1% formic acid in methanol as mobile phase B at a flow rate of 0.3 ml/min using gradient mode of elution at a total run time of 18 minutes. Six nitrosamine impurities are successfully ionized and quantified in positive mode of atmospheric pressure chemical ionization (APCI) using multiple reaction monitoring (MRM). Method validation is performed as per ICH guidelines evaluating the limit of quantification and detection and found to give good S/N ratios with good linearity range of 0.002 - 2 ppm with regression coefficient >0.99 for all the six nitrosamine impurities. Method recoveries are established using three-step sample preparation protocol and are found to be satisfactory within 80% - 120%. The method can be used routinely applied for the detection of Nitrosamines in Telmisartan at a concentration of 1.5 ng/ml (0.03 ppm with respect to telmisartan concentration of 50 mg/ml).
- U.S. Food and Drug Administration (2008) Guidelines for Industry; Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches (Draft). U.S. Food and Drug Administration, Silver Spring.
- United States Department of Health and Human Services, Food and Drug Administration (2008) Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches. United States Department of Health and Human Services, Food and Drug Administration, Silver Spring.
- Note for Guidance on Pharmaceutical Development, EMEA/CHMP/167068/2004.
- ICH M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. European Medicines Agency, London.
- Mirvish, S.S. (1975) Formation of N-Nitroso Compounds: Chemistry, Kinetics, and in Vivo Occurrence. Toxicology and Applied Pharmacology, 31, 325-351. https://doi.org/10.1016/0041-008X(75)90255-0
- Mitch, W.A. and Sedlak, D.L. (2002) Formation of N-Nitrosodimethylamine (NDMA) from Dimethylamine during Chlorination. Environmental Science & Technology, 36, 588-595. https://doi.org/10.1021/es010684q
- U.S. Food and Drug Administration (2019) FDA Updates and Press Announcements on Angiotensin II Receptor Blocker (ARB) Recalls (Valsartan, Losartan, and Irbesartan). https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan
- European Medicines Agency (2018) EMA 485921. Update on Review of Valsartan Medicines Following Detection of Impurity in Active Substance, EMA/485921/2018. European Medicines Agency, London.
- European Medicines Agency (2018) EMA 643116. EMA Review of Impurities in Sartan Medicines. EMA/643116/2018, European Medicines Agency, London.
- U.S. Food and Drug Administration (2021) Control of Nitrosamine Impurities in Human Drugs: Guidance for Industry. U.S. Food and Drug Administration, Silver Spring. https://www.fda.gov/media/141720/download
- Bergovac, M., Knezevic, A., Plavec, D. and Trkulja, V. (2009) Telmisartan in Daily Clinical Practice: Factors Affecting Efficacy in Treatment of Primary Arterial Hypertension. Journal of Postgraduate Medicine, 55, 27-32. https://doi.org/10.4103/0022-3859.43547
- Jugdutt, B.I. (2010) Clinical Effectiveness of Telmisartan Alone or in Combination Therapy for Controlling Blood Pressure and Vascular Risk in the Elderly. Clinical Interventions in Aging, 5, 403-416. https://doi.org/10.2147/CIA.S6709